TITLE
Optimizing Outcomes in Complement-Mediated Kidney Disease: Biomarkers, Emerging Therapies, and Collaborative Care

PROGRAM PARTNERS
This activity was developed by the National Kidney Foundation, in collaboration with RealCME

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
This activity is supported by an educational grant from Novartis

Release Date:  February 5, 2026

Expiration Date:  October 4, 2026

STATEMENT OF NEED
The treatment landscape for CMKDs is rapidly evolving with recent therapeutic breakthroughs, such as FDA approvals for C3G and IgA nephropathy. A new era of targeted treatment options presents a challenge for clinicians to stay current with the latest developments. While traditional immunosuppressive agents have shown mixed results, new complement inhibitors targeting various points in the cascade offer the potential for more precise and personalized treatment. Despite these advances, major gaps remain in early diagnosis, biomarker-driven classification, optimal therapeutic integration, and long-term management

This program will connect CMKD subject matter experts with less experienced nephrology clinicians to discuss the clinical complexities of CMKDs with a particular focus on strategies for timely and accurate differential diagnosis of CMKD, evaluation of new and emerging treatment options, application of biomarker testing, and incorporation of patient perspectives into practice. It also acknowledges that there are varying degrees of specialization among nephrologists regarding CMKDs and establishes meaningful connections between CMKD experts with those who will be responsible for surveillance and assessment.

EDUCATIONAL OBJECTIVES

APPLY knowledge of the alternative complement pathway, including the forms, classifications, and post-transplant recurrence of C3G, aHUS, IgAN, and MN , to improve diagnostic accuracy  and disease management  of CMKD.

IMPLEMENT evidence-based diagnostic strategies, including biomarker testing and histological analysis, to differentiate CMKD subtypes and support specialized care.

EVALUATE the clinical data supporting current and emerging complement-targeted therapies and integrate findings into individualized treatment plans that optimize patient outcomes and quality of life for CMKD patients.

ESTABLISH effective communication and collaboration strategies within a multidisciplinary team to optimize the care of patients with CMKD.

EMPLOY SDM techniques and patient education strategies to develop personalized treatment plans that consider patient preferences and goals in the management of CMKD.

TARGET AUDIENCE
Nephrologists, nephrology fellows, renal pathologists, nephrology APPs, nephrology nurses, specialty pharmacists and managed care specialty clinicians

FACULTY

PATIENT PARTICIPANTS

Lindsey Fuller, MS
Educator, Decatur Public Schools District 61
Blue Mound, IL
Disclosure: Patient Experience Consultant, Renal Advisory Committee: Novartis; Patient Experience Consultant, Patient Advisory Committee: Apellis

Alison Hovery
Executive Assistant, Industrial Mechanical, Inc.
Auburn, GA
Disclosure: Has no financial relationships with ineligible companies.

CONTENT REVIEWER

Prudence King, MSN, AGPCNP-BC
Advanced Clinical Practitioner, Medspace
Independence, KY
Disclosure: Has no financial relationships with ineligible companies.

Catherine Wells, DNP, ACNP, CNN-NP, FNKF
Assistant Professor, University of Mississippi Medical Center
Pearl, MS
Disclosure: Has no financial relationships with ineligible companies.

Anna Gaddy, MD
Assistant Professor, Medical College of Wisconsin
Wauwatosa, WI
Disclosure: Advisory Board: Travere, Vera;  Consultant/Speaker: Otsuka; Site Primary Investigator: Biogen Pharmaceuticals; Ended- July 2024 Advisory Board: Calliditas
 

PLANNERS

Erin Ash, MD
Medical Director, RealCME
New York, NY
Disclosure: Has no financial relationships with ineligible companies.

Abby Smith
Project Manager, RealCME
New York, NY
Disclosure: Has no financial relationships with ineligible companies.

Kim Dunisch, MBA
Continuing Education Director, National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with ineligible companies.

James Papanikolaw, MA
Senior Director, Content Development, Kidney Learning Solutions, National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with ineligible companies.

TECHNICAL WRITER

Whitney Smalley-Freed, PhD
Principal, Precise Medical Writing
Saguache, CO
Disclosure: Has no financial relationships with ineligible companies.

DECLARATION OF DISCLOSURE
It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

All of the relevant financial relationships listed for faculty and planners have been mitigated according to NKF policies. Please see the faculty tab within each course for all disclosure information.

PROVIDERSHIP
This educational activity is provided and solely accredited by the National Kidney Foundation.

ACCREDITATION STATEMENT
In support of improving patient care, the National Kidney Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), to program to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENT

Physician
The National Kidney Foundation designates this other/blended activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurse Practitioner, Nurse
Awarded 4.75 contact hour of continuing nursing education

Physician Assistant
National Kidney Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Pharmacist
This knowledge-based enduring activity has been assigned Universal Activity Number (JA0004461-0000-26-002-H01-P), for 4.75 contact hours (0.475 CEUs). To receive credit, learners must read the activity overview, learning objectives and faculty disclosures, complete the pre-test, review the content, complete the post-test with a minimum score of 70% (post-test may be taken up to 3 times) and electronic activity evaluation. An NABP eProfile ID and date of birth in MMDD format are prerequisites for receiving continuing pharmacy education credits. All credit awarded to participants must be uploaded to CPE Monitor™ within 30 days of the activity date, so pharmacists are required to provide their e-Profile ID and date of birth (MMDD) at the time of the activity.  Please contact cmeinfo@kidney.org if you do not see activity information listed in your profile within 30 days.  For more information and to set up your e-Profile visit: www.MyCPEmonitor.net.
 

DISCLOSURE OF UNLABELED USE
During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER
The faculty and National Kidney Foundation (NKF) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information contained in this NKF educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments.  This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT

Estimated time to complete this activity:  4.75 hours

Learners will review the materials on accreditation information, target audience, learning objectives, and disclosure information; complete the Baseline Assessment; review the video content within each module; complete the Final Assessment (minimum score of 70% required; learners will only have 3 attempts to pass the Final Assessment), Post Group Assessment and evaluation to successfully earn credit.

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Three (3) Self-Study Modules: 15 minutes each for a total of up to 0.75 hours of CME
• Two (2) Live Group Discussions: 45 minutes each for a total of up to 1.50 hour of CME
• Two (2) Group Challenges: 30 minutes each for a total of up to 1.00 hour of CME
• Action Plan development: 30 minutes for a total of 0.50 hours of CME

If you are seeking credit, you must complete the assessment and evaluation at the conclusion of the activity. Your certificate can be printed immediately.


PRIVACY STATEMENT
The National Kidney Foundation (NKF) is committed to protecting the privacy and confidentiality of personal information collected in connection with its continuing medical education (CME) activities. NKF collects and uses personal information in accordance with applicable privacy laws and regulations and maintains administrative, technical, and physical safeguards to protect that information from unauthorized access, use, or disclosure. Personal information collected through NKF CME activities is used solely for educational, accreditation, reporting, and quality improvement purposes. NKF does not sell or rent personal information to third parties. Information may be shared with trusted service providers or accreditation bodies only as necessary to administer the activity, meet accreditation requirements, or comply with legal or regulatory obligations. By participating in this CME activity, you acknowledge and agree to the collection and use of your information as described in this statement.

COLLECTION AND USE OF YOUR PERSONAL INFORMATION

NKF may collect the following types of personal information in connection with this CME activity:

• Contact information (name, email, professional credentials and organization)
• Professional information (specialty, role and practice setting)
• Participation and engagement data (registration status, attendance, activity completion, and assessment response)
• Evaluation and outcomes data (pre- and post-activity assessments, confidence measures, and follow-up surveys)
   

This information is collected and used for the following purposes:

• To register you for the CME activity and verify participation
• To award, track, and report continuing education credit
• To evaluate educational effectiveness and measure outcomes in accordance with accreditation requirements
• To support quality improvement and future educational planning
• To meet reporting obligations to accrediting bodies and funding entities, when applicable

Data may be reported in aggregate or de-identified form for outcomes analysis, accreditation reporting, or research and quality improvement purposes. Individual-level data will not be publicly disclosed. Participation in evaluations and outcomes surveys may be required to claim CME credit.

CONTACT INFORMATION
For questions regarding CME credit, contact the National Kidney Foundation at cmeinfo@kidney.org

For technical questions related to this activity, please contact support@gathered.com